Overview
PNC-27 is an experimental synthetic 32-amino-acid peptide combining a p53 tumor-suppressor domain with a membrane-penetrating transmembrane sequence.
What problem it targets: It is researched exclusively in oncology laboratories for its ability to selectively target and destroy malignant cancer cells while sparing healthy tissue.
What It Does
• Binds HDM-2 on cancer cell membranes: Seeks out HDM-2 (MDM2) proteins uniquely expressed on the outer cell membranes of malignant cancer cells.
• Physically punctures cancer cell membranes: Upon binding, it inserts itself into the lipid bilayer, forming transmembrane pores (membranolysis) that rapidly rupture the cancer cell.
• Spares healthy, non-cancerous cells: Normal somatic cells do not express significant HDM-2 on their outer surfaces, allowing PNC-27 to pass without causing membrane damage in dish studies.
• Realistic expectations: PNC-27 is an experimental laboratory research compound with zero approved clinical indications. The FDA has warned against unapproved consumer use due to a lack of validated human safety data.
Reconstitution
| Vial size | BAC water / Solvent | Concentration | Note |
|---|---|---|---|
| 5 mg | + 2.5 mL | 2 mg/mL | Store cold/dark. No validated human dose. |
Solubility & Preparation Notes
PNC-27 is an amphipathic peptide designed specifically to enter lipid membranes. Because of its hydrophobic transmembrane tail, it often resists neutral water reconstitution and tends to cloud or precipitate.
Solution: Requires an acidic solubilization step first to disperse the hydrophobic domain.
Protocol
Handling & Stacking
- Freeze-dried: -20°F or colder ideal.
- Reconstituted: refrigerate, best used within ~2 weeks (community estimate), kept cold and dark; fragile, potency fades before the 28-day sterility limit.
- Unknown in humans.
- Selective cancer-cell killing in the lab has not been validated as safe or effective in people.
- Supply math Not applicable, no validated human dosing.
- Research compound only.
